Hematotesticular

DEHP orally administered to dams should cross various biological barriers before reaching fetuses gonads (including digestive tract of the dams, blood maternal circulation, placental barrier, blood embryonic circulation, embryo hematotesticular barrier) leading us to use a high dose (more typical to a toxicological risk assessment study) for this first ‘‘proof of concept” study.